Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a...

Полное описание

Библиографические подробности

Главные авторы:	Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2026-05-01
Серии:	Cancer Medicine
Предметы:	fruquintinib metastatic colorectal cancer SBRT TAS‐102
Online-ссылка:	https://doi.org/10.1002/cam4.71884
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!